CAS 396091-73-9

Pasireotide

Description:

Pasireotide is a synthetic cyclic octapeptide and a somatostatin analog, primarily used in the treatment of acromegaly and Cushing's disease. It functions by binding to somatostatin receptors, particularly subtype 5, which inhibits the secretion of growth hormone and adrenocorticotropic hormone (ACTH). This action helps to regulate hormone levels in patients with excess hormone production. Pasireotide is characterized by its ability to exhibit a broader receptor binding profile compared to natural somatostatin, which enhances its therapeutic efficacy. The compound is typically administered via subcutaneous injection and has a relatively long half-life, allowing for less frequent dosing. Its pharmacokinetics can be influenced by factors such as liver function and the presence of other medications. Common side effects may include gastrointestinal disturbances, hyperglycemia, and potential impacts on liver function. Overall, pasireotide represents a significant advancement in the management of specific endocrine disorders, providing an alternative for patients who do not respond adequately to other treatments.

Pasireotide

CAS: 396091-73-9

The somatostatin analog pasireotide is a multi-receptor ligand with high binding affinity for somatostatin receptor subtypes sst(1,2,3) and sst(5). It suppresses ACTH secretion from pituitary adenomas. CAS-number (diacetate): 396091-77-3. Bachem provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Bachem against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Formula: C₅₈H₆₆N₁₀O₉

Purity: 98.4%

Color and Shape: Beige Lyophilisate

Molecular weight: 1047.22

Ref: 01-4060221

Pasireotide

CAS: 396091-73-9

Pasireotide (SOM 230) is a cyclohexapeptide, mimicking somatostatin with high affinity for sst1/2/3/4/5 receptors (pKi=8.2/9.0/9.1/<7.0/9.9).

Formula: C₅₈H₆₆N₁₀O₉

Purity: 98%

Color and Shape: Solid

Molecular weight: 1047.21

Ref: TM-T12370

Pasireotide-d7

CAS: 396091-73-9

Formula: C₅₈H₅₉D₇N₁₀O₉

Molecular weight: 1054.27

Ref: 4Z-PP-266002

Pasireotide

CAS: 396091-73-9

Formula: C₅₈H₆₆N₁₀O₉

Molecular weight: 1047.23

Ref: 4Z-PP-266001

Pasireotide TFA Salt

Controlled Product

CAS: 396091-73-9

Applications Pasireotide can be used in biological study of long-term treatment of Cushing's disease with pasireotide, 5-yr results from open-label extension study of Phase III trial. References Petersenn, S., et al.: Endocrine, 57, 156 (2017)

Formula: C₅₈H₆₆N₁₀O₉·XC₂HF₃O₂

Color and Shape: Neat

Molecular weight: 1047.21

Ref: TR-P211010

Pasireotide-d7

Controlled Product

CAS: 396091-73-9

Formula: C₅₈H₅₉D₇N₁₀O₉

Color and Shape: Neat

Molecular weight: 1054.25

Ref: TR-P211012